A: Nothing upfront
Importantly, tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pentameric nCRP and CRP peptides 7782, 174185, and 201206 can control the inflammatory response resolving inflammation by reducing inflammatory cell endothelial adhesion and tissue migration, and the described CRP-mediated enhanced monocyte chemotaxis could be explained by local generation of mCRP (190, 191)
However, retinoids offer additional benefits including texture improvement and dark spot reduction that copper peptides don't provide as strongly
In 2014, the FDA granted approval for two drugs, pirfenidone and nidazanib, as therapeutic options for PF treatment [9]
These peptides are used off-label in clinical settings